

### Remarks

Support for the addition of New Claims 30 through 65 may be found generally through out the specification; specifically, on pages 14-30 and pages 91-107; and more specifically, in the following corresponding locations in the specification.

Claims 30 and 49 - pg 97, line 6-9

Claims 31 and 50 - pg 19, lines 6-9

Claims 32 and 51 - pg 98, lines 15-18

Claims 33 and 52 – pg 16, lines 6-7

Claims 34 and 53 – pg 16, lines 6-7

Claims 35 and 54 – pg 19, lines 14-25

Claims 36 and 55 – pg 16, line 8; and pg 20, line 5

Claims 37 and 56 – pg 19, line 33 - pg 20, lines 6-2; and pg 97, lines 29-34

Claims 38 and 57 – pg 18, lines 3-16

Claims 39-46 and 58-65 – pg 29, lines 1-6

Claims 47 and 66 – pg 26, line 18 - pg 28, line 34

Claims 48 and 67 – pg 103-107

Claims 1-29 have been cancelled without waiver or prejudice and without admitting anticipation or obviousness. The subject matter has been limited to the use of neuropeptide Y inhibitors in response to a second restriction requirement within the Group I election in the pending parent application. Applicants reserve the right to claim non-elected subject matter included in the cancelled claims in subsequent divisional applications.

Respectfully Submitted By:

October 15, 2003



Arlene K. Musser  
Registration No. 37,895

Pfizer Inc.  
Patent Department, MS: 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871